Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

By U. Rix, O. Hantschel, G. Dürnberger, Lily L. Remsing Rix, Melanie Planyavsky, Nora V. Fernbach, I. Kaupe, K. Bennett, P. Valent, Jacques Colinge and 2 more. Blood, 2007

706 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/6a8fc6b7fbb5b191ecd4b1738dc1d891034a7b1b